第5章 miRNAハイライト、課題、研究開発における進歩

調査分析

参考

目次

New to Insight Pharma Reports is: MicroRNA: An Insight to miRNA-Based
Microarrays, Diagnostics and Therapeutics. This report covers the specifics of
microRNA (miRNA) as it is a relatively new space in heavy pursuit of research
due to its versatility and stability, properties that are unique to miRNAs
compared to other RNA components. miRNA's non-coding nature and ability to
affect genetic expression make it a novel candidate for use as a biomarker for
a variety of diseases. This prompted the pursuit of miRNA-based microarrays
and diagnostics for the advancement in therapeutic development. Furthermore
there are a number of academic laboratories not only validating miRNAs, but
also identifying them in a number of diseases and examining their molecular
actions in the presence of other molecules. This report is broken up into
several parts, highlighting miRNA in several areas of research.

After covering background information, the second and third parts of this
report expand upon several microarrays and diagnostics for specific analysis
and therapeutic development. Several companies featured in this section
include:

Affymetrix

Exiqon

Diamir

Rosetta Genomics

Eisai

Chapters within these sections feature company backgrounds and highlight
proprietary technologies and platforms. Additionally, several advantages and
limitations are also discussed. More significantly, these chapters are
accompanied by interviews with company representatives, exclusively conducted
for this report.

The fourth part of this report explores the academic, research and community
perspectives. Although not developing diagnostics per se, academia is
diligently investigating several aspects of miRNAs including their molecular
properties for use as biomarkers for neurodegenerative diseases, diabetes, and
even cancer. Universities and research institutes included in this area are:

Stony Brook University School of Medicine

Grand Valley State University

Van Andel Research Institute

Also included in these sections are interviews with experts in leading
research from these universities. From a community perspective, Dr.
Argyropoulos, a Medical Affairs Consultant, provides insight to the rapidly
growing space and rising opportunities.

Finally, the report concludes with an in depth analysis of survey results.
With 152 researchers, these results provide an overall perspective of the
research community, capturing a number of miRNA applications, challenges
afloat in the industry, and miRNA mechanisms of study.